A Preliminary Study on the Effect of CD47-Targeted Immunotherapy on Oral-Gut Microbiota

CHEN Jing, REN Min, PENG Xian, REN Biao, CHENG Lei

Abstract

To study the effects of CD47-targted immunotherapy on the oral-gut microbiota of immune-competent mice.   Methods  A peritoneal metastatic colon cancer model was constructed in immune-competent mice. Anti-CD47 monoclonal antibody was intraperitoneally administered to the mice in the treatment group, while PBS was administered to mice in the control group. Tumor growth was documented with small animal live imaging technology. 16S rRNA sequencing technology was used to analyze the composition and diversity of oral-gut microbiota.   Results  The alpha diversity of oral microbes in the anti-CD47 monoclonal antibody treatment group decreased, and the difference was statistically significant. There was no significant change in the alpha diversity of gut microbes. Differential species analysis showed significantly decreased abundance of Staphylococcus, Jeotgalicoccus, and Sporosarcina in the oral microbiota of mice in the treatment group compared to that of mice in the control group. The abundance of Bacteroides in the gut microbiota was significantly higher in the treatment group.   Conclusion  CD47-targted immunotherapy has a rather significant impact on the diversity of oral microbiota in mice, but does not have significant impact on the species diversity of gut microbiota.

 

Keywords: CD47, Immunotherapy, Oral microbiota, Gut microbiota

 

Full Text:

PDF


References


LEVY M， THAISS CA， ELINAV E. Metagenomic cross-talk: The regulatory interplay between immunogenomics and the microbiome. Genome Med， 2015， 7: 120[2021-07-15]. https://doi.org/10.1186/s13073-015-0249-9.

BELKAID Y， HARRISON O J. Homeostatic immunity and the microbiota. Immunity，2017，46(4): 562–576.

WU X， GU Z， CHEN Y， et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J，2019，17: 661–674.

SONDAK V K， SMALLEY K S M， KUDCHADKAR R， et al. Ipilimumab. Nat Rev Drug Discov，2011，10(6): 411–412.

ZHANG W， HUANG Q， XIAO W， et al. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis . Front Immunol， 2020， 11: 18[2021-07-15]. https://doi.org/10.3389/fimmu.2020.00018.

FENG M， JIANG W， KIM B Y S， et al. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer，2019，19(10): 568–586.

FIALA O， SOREJS O， SUSTR J， et al. Immune-related adverse effects and outcome of patients with cancer treated with immune checkpoint inhibitors. Anticancer Res，2020，40(3): 1219–1227.

SPAIN L， DIEM S， LARKIN J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev，2016，44: 51–60.

VETIZOU M， PITT J M， DAILLERE R， et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science，2015，350(6264): 1079–1084.

SOULARUE E， LEPAGE P， COLOMBEL J F， et al. Enterocolitis due to immune checkpoint inhibitors: A systematic review. Gut，2018，67(11): 2056–2067.

CHEN S， ZHOU Y， CHEN Y， et al. Fastp: An ultra-fast all-in-one FASTQ preprocessor. Bioinformatics，2018，34(17): i884–i890.

MAGOC T， SALZBERG S L. FLASH: Fast length adjustment of short reads to improve genome assemblies. Bioinformatics，2011，27(21): 2957–2963.

EDGAR R C. UPARSE: Highly accurate OTU sequences from microbial amplicon reads. Nat Methods，2013，10(10): 996–998.

STACKEBRANDT E， GOEBEL B M. Taxonomic note: A place for DNA-DNA reassociation and 16S rRNA sequence analysis in the present species definition in bacteriology. Microbiol Society，1994，44(4): 846–849.

WANG Q， GARRITY G M， TIEDJE J M， et al. Naïve Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol，2007，73(16): 5261–5267.

SCHLOSS P D， WESTCOTT S L， RYABIN T， et al. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol，2009，75(23): 7537–7541.

SCHLOSS PD. Reintroducing mothur: 10 years later. Appl Environ Microbiol， 2020， 86(2): e02343-19[2021-07-15]. https://doi.org/10.1128/AEM.02343-19.

CAPORASO J G， KUCZYNSKI J， STOMBAUGH J， et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods， 2010，7(5): 335–336.

DIXON P. VEGAN, a package of R functions for community ecology. Journal of Vegetation Science，2003，14(6): 927–930.

SEGATA N， IZARD J， WALDRON L， et al. Metagenomic biomarker discovery and explanation. Genome Biol， 2011， 12(6): R60[2021-07-15]. https://doi.org/10.1186/gb-2011-12-6-r60.

RAUTAVA J， PINNELL L J， VONG L， et al. Oral microbiome composition changes in mouse models of colitis. J Gastroenterol Hepatol， 2015，30(3): 521–527.

SAID H S， SUDA W， NAKAGOME S， et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res，2014，21(1): 15–25.

ZHAO F， DONG T， YUAN KY， et al. Shifts in the Bacterial Community of Supragingival Plaque Associated With Metabolic-Associated Fatty Liver Disease. Front Cell Infect Microbiol， 2020， 10: 581888[2021-07-15]. https://doi.org/10.3389/fcimb.2020.581888.

ACHARYA C， SAHINGUR SE， BAJAJ JS. Microbiota， cirrhosis， and the emerging oral-gut-liver axis. JCI Insight， 2017， 2(19): e94416[2021-07-15]. https://doi.org/10.1172/jci.insight.94416.

LE BARS P， MATAMOROS S， MONTASSIER E， et al. The oral cavity microbiota: Between health, oral disease, and cancers of the aerodigestive tract. Can J Microbiol，2017，63(6): 475–492.

FLEMER B， WARREN R D， BARRETT M P， et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut，2018，67(8): 1454–1463.

CHEN Y， CHEN X， YU H， et al. Oral microbiota as promising diagnostic biomarkers for gastrointestinal cancer: A systematic review. Onco Targets Ther，2019，12: 11131–11144.

CHAPUT N， LEPAGE P， COUTZAC C， et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol，2017，28(6): 1368–1379.

DUBIN K， CALLAHAN MK， REN B， et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nature Commun， 2016， 7: 10391[2021-07-15]. https://doi.org/10.1038/ncomms10391.

MARTINS F， SOFIYA L， SYKIOTIS G P， et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol，2019，16(9): 563–580.

ZHANG M， HUTTER G， KAHN SA， et al. Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo. PLoS ONE， 2016， 11(4): e0153550[2021-07-15]. https://doi.org/10.1371/journal.pone.0153550.

JOSEPH S， ADUSE-OPOKU J， HASHIM A， et al. A 16S rRNA Gene and Draft Genome Database for the Murine Oral Bacterial Community. mSystems， 2021， 6(1): e01222-20[2021-07-15].https://doi.org/10.1128/mSystems.01222-20.

LI Y， HE J， HE Z， et al. Phylogenetic and functional gene structure shifts of the oral microbiomes in periodontitis patients. ISME J，2014，8(9): 1879–1891.

DUTZAN N， KAJIKAWA T， ABUSLEME L， et al. A dysbiotic microbiome triggers TH17 cells to mediate oral mucosal immunopathology in mice and humans. Sci Transl Med， 2018， 10 (463): eaat0797[2021-07-15]. https://doi.org/10.1128/10.1126/scitranslmed. aat0797.

LI B， GE Y， CHENG L， et al. Oral bacteria colonize and compete with gut microbiota in gnotobiotic mice. Int J Oral Sci， 2019， 11(1): 10[2021-07-15]. https://doi.org/10.1038/s41368-018-0043-9.


Refbacks

  • There are currently no refbacks.